Table 6.
Correlation between immunohistochemical scores of biological markers in tumors after treatment and response to exemestane
| PR (n = 6) Mean ± SD (median; range) | SD (n = 9) Mean ± SD (median; range) | P‐values† | P‐values‡ | |
|---|---|---|---|---|
| ERα | 6.8 ± 1.9 | 6.9 ± 1.1 | 0.58 | 0.94 |
| pERα Ser118 | 4.3 ± 1.8 | 4.8 ± 1.7 | 0.55 | 0.63 |
| pERα Ser167 | 5.5 ± 1.8 | 5.6 ± 1.4 | 0.95 | 0.95 |
| ERβ1 | 3.0 ± 3.0 | 3.9 ± 2.7 | 0.59 | 0.56 |
| ERβcx/β2 | 1.7 ± 2.0 | 1.4 ± 2.2 | 0.79 | 0.84 |
| PgR | 2.5 ± 2.3 | 2.3 ± 2.0 | 0.90 | 0.88 |
| AR | 2.5 ± 0.5 | 2.9 ± 1.1 | 0.56 | 0.42 |
| AIB1 | 2.3 ± 2.6 | 0.4 ± 1.3 | 0.08 | 0.08 |
| Aromatase (cancer) | 4.8 ± 0.4 | 4.4 ± 1.1 | 0.67 | 0.44 |
| Aromatase (stroma) | 2.3 ± 0.8 | 3.1 ± 1.5 | 0.27 | 0.26 |
| HER2 | 1.0 ± 0.0 | 0.4 ± 0.5 | 0.031* | 0.024* |
| pAkt | 1.7 ± 2.6 | 1.0 ± 1.3 | 0.89 | 0.52 |
| pMAPK | 1.3 ± 1.4 | 1.4 ± 1.5 | 0.80 | 0.89 |
| Ki67 | 1.5 ± 0.5 | 1.7 ± 0.7 | 0.69 | 0.63 |
| Cyclin D1 | 3.8 ± 1.8 | 4.0 ± 1.4 | 0.95 | 0.85 |
| p53 | 0.2 ± 0.4 | 0.0 ± 0.0 | 0.22 | 0.23 |
| Bcl2 | 3.3 ± 1.6 | 1.9 ± 1.3 | 0.10 | 0.08 |
| Stat5 (cytoplasm) | 5.0 ± 0.0 | 3.2 ± 2.4 | 0.07 | 0.10 |
| Stat5 (nuclei) | 5.0 ± 0.0 | 4.6 ± 0.7 | 0.13 | 0.16 |
| IGFBP5 (cytoplasm) | 5.0 ± 0.0 | 3.3 ± 2.1 | 0.030* | 0.7 |
| IGFBP5 (nuclei) | 5.0 ± 0.0 | 3.7 ± 1.6 | 0.020* | 0.06 |
*P < 0.05 is considered significant. †Mann–Whitney U‐test. ‡Unpaired t‐test. AIB1, amplified in breast cancer 1; AR, androgen receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor type 2; IGFBP5, insulin‐like growth factor binding protein 5; pAkt, phosphorylated Akt; pER, phosphorylated ER; PgR, progesterone receptor; pMAPK, phosphorylated MAPK; Ser, serine; Stat5, signal transducer and activator of transcription 5.